Gain Therapeutics Buy Rating Reaffirmed at Roth Mkm
| GANX Stock | USD 2.44 0.01 0.41% |
Slightly above 51% of Gain Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Gain Therapeutics suggests that many traders are impartial. Gain Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Gain Therapeutics' earnings reports, geopolitical events, and overall market trends.
Gain |
Roth Mkm restated their buy rating on shares of Gain Therapeutics in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a 7.00 price target on the stock. Other research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and set
Read at thelincolnianonline.com
 |
Gain Therapeutics Fundamental Analysis
We analyze Gain Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Gain Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Gain Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gain Therapeutics stock to make a market-neutral strategy. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics with similar companies.
Peers
Gain Therapeutics Related Equities
| CUE | Cue Biopharma | 25.90 | ||||
| INAB | In8bio | 20.69 | ||||
| LTRN | Lantern Pharma | 12.03 | ||||
| MOLN | Molecular Partners | 3.90 | ||||
| INBX | Inhibrx | 2.29 | ||||
| BIVI | Biovie | 2.29 | ||||
| ELVN | Enliven Therapeutics | 1.80 | ||||
| MNOV | MediciNova | 1.41 | ||||
| NAMS | NewAmsterdam Pharma | 0.35 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.82 | ||||
| CSBR | Champions Oncology | 2.77 | ||||
| CELC | Celcuity LLC | 3.30 |
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.